Appili Therapeutics Inc. (APLI)
Market Closed
15 Jun, 20:00
TSX TSX Primary 
OTC PINK CA$
0. 01
0
0%
CA$
4.24M Market Cap
- P/E Ratio
- Div Yield
247,000 Volume
- Eps
CA$ 0.01
Previous Close Want to track APLI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
APLI closed yesterday higher at CA$0.01, an increase of 0% from Friday's close, completing a monthly increase of 0% or CA$0. Over the past 12 months, APLI stock lost -40%.
APLI is not paying dividends to its shareholders.
The last earnings report, released on Feb 12, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on TSX (CAD).
Appili Therapeutics Inc. (APLI) FAQ
What is the stock price today?
The current price is CA$0.01.
On which exchange is it traded?
Appili Therapeutics Inc. is listed on TSX.
What is its stock symbol?
The ticker symbol is APLI.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.24M.
Has Appili Therapeutics Inc. ever had a stock split?
No, there has never been a stock split.
Appili Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Donald D. Cilla Jr. Pharmd CEO | TSX Exchange | CA03783R1073 ISIN |
| CA Country | 8 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Appili Therapeutics Inc. is a biopharmaceutical company dedicated to addressing unmet needs in infectious disease management through the acquisition and development of novel medications. Established in 2015, the company is strategically positioned in Halifax, Canada, focusing its efforts on advancing its portfolio of anti-infective drugs. These endeavours underscore Appili Therapeutics Inc.'s commitment to public health and innovation in the face of growing infectious disease challenges globally.
Products and Services
- ATI-1501: This is a taste-masked liquid oral suspension of metronidazole, designed to improve patient compliance by offering a more palatable formulation. Targeting anaerobic bacterial, protozoal, and parasitic infections, ATI-1501 represents an innovative approach to treating these stubborn and often severe conditions.
- ATI-1801: Currently in Phase III clinical trials, ATI-1801 is a novel topical formulation of paromomycin aimed at treating cutaneous leishmaniasis as well as other disfiguring skin infections. This product stands as a testament to Appili Therapeutics Inc.'s dedication to developing advanced treatment options for neglected tropical diseases and skin conditions.
- ATI-1701: As a live-attenuated vaccine in preclinical trials, ATI-1701 targets Francisella tularensis, the bacterium responsible for tularemia. This vaccine candidate highlights the company’s innovative efforts in preventive medicine, aiming to offer protection against this potentially serious and sometimes life-threatening disease.
Contact Information
Address: #21-1344 Summer Street
Phone: 902-442-4655
Website: https://www.appilitherapeutics.com
